Amedisys (AMED) Q2 Revenue Tops 5%

Amedisys (NASDAQ:AMED), a leading provider of home health, hospice, and high acuity post-acute care services, reported quarterly earnings for the period ending June 30, 2025, on July 29, 2025. The most significant news is that the company outperformed market expectations on both revenue and adjusted profitability, even as merger-related costs weighed on GAAP results. GAAP revenue reached $621.9 million, ahead of the $611.99 million GAAP consensus, and Non-GAAP EPS was $1.54, well over the $1.36 analyst forecast (non-GAAP). While core operations showed strength, reported GAAP net income dropped to $28.1 million from $32.3 million a year ago, with the decrease driven by $26.3 million in expenses linked to the pending UnitedHealth Group merger. Overall, the quarter demonstrated continued momentum in Amedisys’s operational performance, but this was tempered by non-operational items and transition uncertainty. Source: Analyst estimates for the quarter provided by FactSet. Amedisys operates a national network of 519 care centers, serving nearly half a million patients each year across 38 states and Washington, D.C. Its primary business lines include home health services, which provide skilled nursing and therapy in patients' homes; hospice care for end-of-life support; and high acuity care, which delivers hospital-level treatment at home through partnerships.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool